Avalo Therapeutics, Inc. current report, 08 August 2019

SEC Filing Summary: Cerecor Inc. (8-K)

Business Context and Reporting Period

This Form 8-K was filed by Cerecor Inc. (Ticker: CERC) on August 8, 2019. The filing serves as a current report announcing the company's financial results for the quarter ended June 30, 2019. The registrant is an emerging growth company incorporated in Delaware.

Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.

Material Changes

The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.

Guidance, Outlook, and Risks

The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the 8-K text itself.

Key Facts for Investor Verification

  • Verify the specific financial results for the quarter ended June 30, 2019, by reviewing the attached press release (Exhibit 99.1).
  • Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
  • Note that the financial data in this filing is not subject to Section 18 liabilities of the Exchange Act.
  • Check the Nasdaq Capital Market listing status for Common Stock (CERC).